Enterprise Value

2.253B

Cash

368.2M

Avg Qtr Burn

N/A

Short % of Float

23.82%

Insider Ownership

11.42%

Institutional Own.

83.53%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Korlym® (Relacorilant) Details
Hypercortisolism, Cushing’s syndrome

Phase 4

Data readout

Relacorilant + Nab-paclitaxel Details
Ovarian cancer, Cancer, Solid tumor/s

Phase 3

Data readout

Korlym® (Relacorilant) Details
Hypercortisolism, Cushing’s syndrome

Phase 3

Data readout

Korlym® (Relacorilant) Details
Hypercortisolism

Big Mover™

Susp. Mover™

Phase 3

Data readout

Miricorilant Details
Non-alcoholic steatohepatitis

Phase 2b

Data readout

Relacorilant (GR antagonist) + Enzalutamide Details
Cancer, Castration-resistant prostate cancer, Solid tumor/s, Prostate cancer

Phase 2

Data readout

Dazucorilant Details
Amyotrophic lateral sclerosis

Phase 2

Data readout

Miricorilant Details
Obesity, Antipsychotic-Induced Weight Gain

Phase 2

Update

Phase 1b

Data readout

Failed

Discontinued